<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388516</url>
  </required_header>
  <id_info>
    <org_study_id>1000039072-ARI</org_study_id>
    <nct_id>NCT02388516</nct_id>
  </id_info>
  <brief_title>Maternal Vitamin D for Acute Respiratory Infections in Infancy</brief_title>
  <acronym>MDARI</acronym>
  <official_title>Maternal Vitamin D for Acute Respiratory Infections in Infancy (MDARI): a Nested Sub-study in a Randomized Controlled Trial of Vitamin D Supplementation During Pregnancy and Lactation in Dhaka, Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a growing body of data suggesting that vitamin D modulates the host's immune
      response to acute respiratory infection (ARI). The primary aim of this study is to determine
      whether maternal vitamin D3 supplementation versus placebo decreases the incidence rate of
      microbiologically confirmed viral-associated ARI among infants in Dhaka, Bangladesh.
      Secondary outcomes include: A) incidence of ARI associated with specific major pathogens, B)
      incidence of clinical ARI (without the need for positive microbiology), and C) quantitative
      density of pneumococcal carriage. Infants will be followed from birth until 6 months of life.
      Among infants who meet at least one of the specific case definitions for ARI (see 'Detailed
      Description' section), nasal swab specimens will be collected. Respiratory samples will be
      analyzed by real-time polymerase chain reaction (qPCR) to identify a 7-virus panel (influenza
      A and B, respiratory syncytial virus, human metapneumovirus, adenovirus, and parainfluenza
      types 1, 2, and 3) plus quantitative density of S. pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, an acute respiratory infection (URTI and/or LRTI) has been clinically defined
      as:

      A) Upper respiratory tract infection (URTI)

      A new-onset illness consisting of at least two of the following clinical criteria at any time
      during a surveillance week:

        -  Caregiver-reported cough;

        -  Caregiver-reported rhinorrhea;

        -  Caregiver-reported nasal congestion; and,

        -  Measured axillary temperature greater than or equal to 37.5Â°C.

      B) Lower respiratory tract infection (LRTI)

        1. New onset clinically-diagnosed LRTI:

             -  Caregiver-reported cough AND/OR difficulty breathing during a surveillance week;
                AND,

             -  Observed lower chest wall indrawing AND/OR elevated respiratory rate (60 breaths
                per minute or greater for infant up to 59 days of age, or 50 breaths per minute or
                greater for infant 60 days of age or older)

        2. Hospitalized LRTI

             -  Hospitalization with physician diagnosis of pneumonia or bronchiolitis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">August 21, 2016</completion_date>
  <primary_completion_date type="Actual">August 21, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiologically confirmed viral acute respiratory infection (URTI and/or LRTI)</measure>
    <time_frame>0 to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ARI with microbiologically confirmed influenza A or B</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARI with microbiologically confirmed RSV</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical URTI and/or LRTI (i.e., no microbiological confirmation)</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical URTI (i.e., no microbiological confirmation)</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical LRTI (i.e., no microbiological confirmation)</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative S. pneumoniae nasal carriage density</measure>
    <time_frame>0 to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia (non-severe) and severe pneumonia or very severe disease</measure>
    <time_frame>2 to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1214</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <condition>Lower Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants born to women enrolled in the MDIG trial (NCT01924013).

          -  Maternal inclusion criteria (at time of enrolment) will be:

          -  At least 18 years of age

          -  17 to 24 completed weeks of gestation

          -  Intends to permanently reside in the trial catchment area for at least 18 months

          -  Family plans to reside in catchment area for the first 6 months postnatal

          -  Provides written informed consent for participation

        Exclusion Criteria:

          -  Mother withdrawn from MDIG trial prior to delivery

          -  Failure to provide consent for participation in sub-study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>26 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaun K Morris, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Roth, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Centre for Diarrhoeal Disease Research, Bangldesh</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Daniel Roth</investigator_full_name>
    <investigator_title>Clinician-Scientist</investigator_title>
  </responsible_party>
  <keyword>Bangladesh</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Acute Respiratory Infections</keyword>
  <keyword>Infancy</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

